The developer of ivermectin is performing late-stage trials on a drug that could actually prevent COVID-19. Merck & Co partnered with Ridgeback Biotherapeutics to develop molnupiravir. Enrollment for late-stage trials for their drug have already started.... The drug, which can be taken via a pill, is now entering late stage trials in the United States as Merck plans to eventually seek FDA approval. Over 1,300 volunteers aged 18 or older will be recruited for the study and live in a house with someone who has a symptomatic case of the COVID-19. Merck also plans to use the drug in some...